Clinical Trial Update: Absolute Bioavailability of YH4808 With Accelerator Mass Spectrometry(AMS)-Based Microdose Study [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial reports the absolute bioavailability of YH4808 using AMS-based microdosing in Gastroesophageal Reflux Disease. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• YH4808

Snippet

Sponsor: Seoul National University Hospital | Conditions: Gastroesophageal Reflux Disease | EARLY_Phase 1 | Status: COMPLETED